Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2054 June 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Febuxostat		
Initial application — Gout Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate) Patient has been diagnosed with gout and		
The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note) The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout.		
Initial application — Tumour lysis syndrome Applications only from a haematologist or oncologist. Approvals valid for 6 weeks. Prerequisites(tick boxes where appropriate)		
Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome		
Patient has a documented history of allopurinol intolerance		
Renewal — Gout Current approval Number (if known):		
Applications from any relevant practitioner. Appro-		
Prerequisites(tick box where appropriate)		
The treatment remains appropriate and the patient is benefitting from treatment		
Renewal — Tumour lysis syndrome		
Current approval Number (if known):		
The treatment remains appropriate and the patient is benefitting from treatment		